

## Skip this form & e-prescribe! <u>Select BioPlus</u> from your EHR!

**NEUROLOGY & MULTIPLESCLEROSIS** 

PATIENT INFORMATI							
Name:		SSN:	SSN:		DOB:		
Address:		City:	City:		State: Zip:		
Home Phone: Cell:		Email:	Email:		Gender: Female Male		
INSURANCE INFORMATION (or attach copy of the cards)							
Primary Insurance: Policy Holder:			Relationship:	Polic	y #:	Group #:	
Secondary Insurance:	Policy Holder:		Relationship:	Polic	y #:	Group #:	
PRESCRIPTION INFORMATION (for IV medication attach a copy of		f the	prescription)				
MS MEDICATIONS         AVONEX® (interferon beta-1a)*       Enroll in Above MS™ 30 mcg (□ PFS □ Pen) Inject IM once weekly         Qty: 4       Refills:         BETASERON® (interferon beta-1b)*       Enroll in BETAPLUS®         Starting Titration: 62.5 mcg SUBQ every other day for weeks 1 and 2, 125 mcg SUBQ every other day for weeks 3 and 4, 187.5 mcg SUBQ every other day for weeks 5 and 6, 250 mcg SUBQ every other week for weeks 7 and 8         Qty: 30 days       Refills: 1         Maintenance Dosing: 250 mcg (1 ml) SUBQ every other day       □ BetaConnect			PONVORY <sup>®</sup> (ponesimod) tablets □ Starting Titration: 2 mg PO day 1 and 2, 3 mg PO day 3 and 4, 4 mg PO day 5 and 6, 5 mg PO day 7, 6 mg PO day 8, 7 mg PO day 9, 8 mg PO day 10, 9 mg PO day 11, 10 mg PO day 12, 13 and 14. Qty: 1 pack □ Maintenance: 20 mg PO once daily Qty: 30 Refills: None □ Starting Dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion □ Maintenance: 600 mg intravenous infusion every 6 months □ Maintenance: 600 mg intravenous infusion every 6 months □ Maintenance: 600 mg intravenous infusion every 6 months □ Maintenance: 600 mg intravenous infusion every 6 months				
Qty: 14 Refills:			Qty:         Refills:           OZOBAX <sup>TM</sup> (backofen) 5 mg/ml Oral Solution              Goal Dose:mg/day (should be divided into 34 doses)				
COPAXONE® (glatiramer acetate)       □ Enroll in Shared Solutions®       □ Enroll in Mylan ADVOCATE®         □ 20 mg SUBQ every day       □ 40 mg SUBQ three times per week       □         Qty: 28 days       Refills:       □			ons: Increase dose slowly every 3 days by 5 mg PO				
Dalfampradine □ 10 mg by mouth every 12 hours Qty: 60 Refills:							
EXTAVIA® (interferon beta-1b) □ Extavia Go Program®         □ Starting Titration: 62.5 mog SUBQ every other day for weeks 1 and 2, 125 mog SUBQ every other day for weeks 3 and 4, 187.5 mog SUBQ every other day for weeks 5 and 6, 250 mog SUBQ every other week for weeks 7 and 8         Refile:       Refile:         □ Maintenance Dosing: 250 mog (1 ml ) SUBQ every other day       0.25 mg PO once a day         Qty: 15       Refile:         FINGOLIMOD® (gilenya)       0.5 mg PO once a day         Qty: 30       Refills:         GILENYA® (fingolimod)       Enroll in Gilenya Go Program®         W: 30       Refills:         KESIMPTA® (ofatumumab)       Sensoreadv® Pen         Starting Dose: 20 mg SUBQ administered monthly starting at week 4			Rebif® (interferon beta-1a) <ul> <li>Enroll in MS LifeLines®</li> <li>PFSRebiject II®*</li> <li>Rebif Rebidose®</li> </ul> Titration Pack:         Goal Dose 22 mog: (Full dose therapy beginning week 5) 4.4 mog/0.1 ml SUBQ three times weekly week 1-2, 11 mog/0.25 ml.SUBQ three times weekly weeks 3.4         Goal Dose 44 mog: (Full dose therapy beginning week 5) 8.8 mog/0.1 ml SUBQ three times weekly week 1-2, 22 mog/0.25 ml three times weekly weeks 3.4           Goal Dose 44 mog: (Full dose therapy beginning week 5) 8.8 mog/0.1 ml SUBQ three times weekly week 1-2, 22 mog/0.25 ml three times weekly weeks 3.4           Qty: 1 pack         Refills: None           Maintenance Dosing:         144 mog 2 2 mog SUBQ three times per week           Qty:         Refills:           "Rebiject (Wil come from MS Lifelines®)           TECFIDERA® (dimethyl fumarate)         120 mg (14 per bottle 7 day supply)         240 mg (60 per bottle 30 day supply)           Starting Dose:         120 mg (14 per bottle 7 day supply)         240 mg (60 per bottle 30 day supply)           Starting Dose:         120 mg (14 per bottle 7 day supply)         240 mg (60 per bottle 30 day supply)           Starting Dose:         120 mg (14 per bottle 7 day supply)         240 mg (60 per bottle 30 day supply)				
Qty:         Refills:            MAVENCLAD® (dadribine) 10 mg tablet □ Take daily by mouth at intervals of 24 hours			Teriflunomide (generic for Aubagio <sup>®</sup> ) □ 7 mg PO once daily, with or without food. Qty: 30 Refills:				
Number of 10 mg tablets per verset.           Number of 10 mg tablets per verset.           Term of 10 mg tablets per verset.	Week 5         Total Tables           Day 4         Day 5         Total Tables           1         0         4         8 (80mg)           1         1         6         12 (120 mg)           1         1         7         14 (140 mg)           1         1         7         15 (150 mg)	VUI Cty: M Qty: A Qty: A Qty: A	AERITY™ (diroximel fumarate) arting Dose: Take 1 capsule (231 mg) orally twice da 06 aintenance Dosing: Take 2 capsules (462 mg) PO 20 armate Maintenance Dosing: Take caps 20	aily for 7 d twice a d ules (	days, then increase to 2 capsules Refills: None	; (462 mg) twice daily.	
□ 100 < 110 2 2 2 2 2 2 10 2 2 2 2 10 10 2 2 2 2	□7-	ZEPOSIA® (ozanimod) - tay titration: Days 1 to 4: Give 0.23 mg PO once daily. days 5 to 7: Give 0.46 mg PO once daily 					
# of tablets: # of cycles:			Oty: 1     Refills: None       Maintenance Dosing: Starting day 8, 0.92 mg PO once daily     Oty: 30       Refills:				
MAYZENT® (siponimod) □ Please complete Mayzent Prescription S         PLEGRIDY® (peginterferon beta-1a)         Induction: □ PFS □ Pen         63 mog SUBQ on day 1, 94 mog SUBQ on day 15         Qty: 1 pack         Maintenance: 125 mog/0.5 ml □ PFS □ Pen         125 mog SUBQ every 14 days, starting day 29 of therapy         Qty: 2		ST SI	OTHER RENGTH: G/DIRECTIONS: FILLS: QUANTITY:			*AVAILABLE IN GENERIC	
As required by your state, Prescriber to check "Dispense as written" or handwrite "Brand Medically Necessary" and sign to prevent generic substitution.							
PHYSICIAN INFORMATION		Inje	<b>:tion Training:</b> 📃 Office t	to Ins	struct 📃 SP to A	Arrange Teaching	
Prescriber Name: P				F	ax:		
Office Contact:							
Address: C				S	tate:	Zip:	
NPI#. 7			<b>#</b> :	S	hip To: Patient	MD Office	
Prescriber Signature: D							